实用老年医学 ›› 2024, Vol. 38 ›› Issue (6): 587-591.doi: 10.3969/j.issn.1003-9198.2024.06.011

• 临床研究 • 上一篇    下一篇

胰激肽原酶治疗老年2型糖尿病轻度认知功能障碍的疗效观察

时雯, 朱平, 周洁, 颜婷, 黄玉杰, 严妍   

  1. 223200 江苏省淮安市,江苏护理职业学院附属淮安医院(淮安市肿瘤医院)内分泌科(时雯,周洁,颜婷,黄玉杰,严妍);
    223200 江苏省淮安市,江苏护理职业学院附属楚州中医院内分泌科(朱平)
  • 收稿日期:2023-08-04 出版日期:2024-06-20 发布日期:2024-06-19
  • 通讯作者: 朱平,Email:18360757374@163.com
  • 基金资助:
    江苏省老年健康科研项目(LKM2022071)

Effect of pancreatic kallidinogenase on mild cognitive impairment in elderly patients with type 2 diabetes mellitus

SHI Wen, ZHU Ping, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan   

  1. Department of Endocrinology, the Affiliated Huai’an Hospital of Jiangsu College of Nursing (Huai’an Cancer Hospital), Huai’an 223200, China (SHI Wen, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan);
    Department of Endocrinology, the Affiliated Chuzhou Hospital of Traditional Chinese Medicine of Jiangsu College of Nursing, Huai’an 223200, China (ZHU Ping)
  • Received:2023-08-04 Online:2024-06-20 Published:2024-06-19
  • Contact: ZHU Ping, Email: 18360757374@163.com

摘要: 目的 探究胰激肽原酶在老年T2DM伴轻度认知功能障碍(MCI)病人中的疗效。方法 选取本院2021年3月至2023年3月间收治的96例老年T2DM伴MCI病人,采用随机数表法分成对照组和观察组,每组各48例。对照组予以常规治疗(盐酸二甲双胍+盐酸多奈哌齐片),观察组在对照组的基础上增加胰激肽原酶治疗。比较2组血糖控制、认知功能、炎症水平、肾功能、胰岛功能及用药安全性。结果 治疗后,2组FPG、HbA1c水平均低于治疗前(P<0.05),但组间差异均无统计学意义(P>0.05)。治疗后,2组胰岛素抵抗指数(HOMA-IR)、S100β蛋白、TNF-α、IL-6、血肌酐(Scr)、胱抑素C(Cys C)水平均低于治疗前,空腹C肽(FCP)水平、胰岛素分泌指数(HOMA-β)及MoCA评分均高于治疗前,且观察组上述指标改善情况均优于对照组,差异均有统计学意义(P<0.05)。2组用药不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 胰激肽原酶可有效提升老年T2DM伴MCI病人的认知功能,同时改善肾功能及胰岛功能,降低炎症水平,且用药安全可控。

关键词: 2型糖尿病, 轻度认知功能障碍, 胰激肽原酶, 炎症水平, 老年人

Abstract: Objective To explore the efficacy of pancreatic kallidinogenase in the elderly patients with type 2 diabetes mellitus (T2DM) combined with mild cognitive impairment (MCI). Methods Ninety-six elderly T2DM patients with MCI admitted to our hospital from June 2021 to June 2023 were enrolled in this study, and they were divided into the control group and the observation group by random number table method, with 48 cases in each group. The control group received routine treatment (metformin combined with donepezil hydrochloride). The observation group received pancreatic kallidinogenase treatment on the basis of the control group. The levels of blood glucose control, cognitive function, inflammatory factors, renal function, islet function and medication safety were compared between the two groups. Results After treatment, the levels of fasting blood glucose and glycosylated hemoglobin in both groups were lower than those before treatment (P<0.05), but there were no statistical differences between the two groups (P>0.05). After treatment, the levels of insulin resistance index (HOMA-IR), S100β protein, tumor necrosis factor-α, interleukin-6, serum creatinine and cystatin C in both groups were lower than those before treatment, and the levels of fasting C-peptide and insulin secretion index (HOMA-β), and the score of Montreal Cognitive Assessment (MoCA) in both groups were higher than those before treatment, especially in the observation group (P<0.05). There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusions Pancreatic kallidinogenase in the clinical treatment of elderly patients with T2DM and MCI can effectively improve the cognitive function, renal function and islet function, reduce the level of inflammation, and the medication is safe and controllable.

Key words: type 2 diabetes mellitus, mild cognitive impairment, pancreatic kininogenase, inflammation level, aged

中图分类号: